Crossmark

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum

Crossref DOI link: https://doi.org/10.1038/s41436-018-0297-9

Published Print: 2019-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Parker, Victoria E.R.

Keppler-Noreuil, Kim M.

Faivre, Laurence

Luu, Maxime

Oden, Neal L.

De Silva, Leena

Sapp, Julie C.

Andrews, Katrina

Bardou, Marc

Chen, Kong Y.

Darling, Thomas N.

Gautier, Elodie

Goldspiel, Barry R.

Hadj-Rabia, Smail

Harris, Julie

Kounidas, Georgios

Kumar, Parag

Lindhurst, Marjorie J.

Loffroy, Romaric

Martin, Ludovic

Phan, Alice

Rother, Kristina I.

Widemann, Brigitte C.

Wolters, Pamela L.

Coubes, Christine

Pinson, Lucile

Willems, Marjolaine

Vincent-Delorme, Catherine

Vabres, Pierre

Semple, Robert K.

Biesecker, Leslie G.
License Information

Text and Data Mining valid from 2019-05-01

Text and Data Mining valid from 2019-05-01

Version of Record valid from 2021-11-24
More Information

This article is maintained by: Elsevier

Article Title: Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum

Journal Title: Genetics in Medicine

CrossRef DOI link to publisher maintained version: https://doi.org/10.1038/s41436-018-0297-9

Content Type: article

Copyright: © 2019, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics